Gleevec (imatinib tablets) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Metastatic or unresectable disease
• Activating KIT mutation present
• Patient has tried at least one systemic regimen such as nivolumab, ipilimumab, pembrolizumab, dabrafenib plus trametinib, vemurafenib plus cobimetinib, or encorafenib plus binimetinib

Approval duration

1 year